earnings time our to publicly good appreciate everyone. and you first taking Nick, to the as We company. traded you, a morning join call Thank
brief the detailed diabetic from results in pipeline discuss data today, peripheral neuropathy, analysis start results I from scientific DPN. our our plan recently recent with foundation. call NYX-XXXX announced a the study the we or on our painful program, will with including then I Company of background the clinical and to During across of patients
from know, not endpoints, meet the release on was disappointment. line DPN you primary As press which data, our of study a the January course did its top
detailed will we data full discuss, are about having actually optimistic as the prospects in now forward the and completed I chronic analysis very of However, set, for NYX-XXXX pain. the path
would getting I like of to Aptinyx. everyone broader Before mission our these detailed into remind at results,
address of the We the are on the developing in focused of novel to unmet disease discovering system. nervous and treatment and needs therapies vast brain
in stage are clinical rapidly comprises that programs development. advancing pipeline Our
of robust our from our are of who product affording from novel candidates of to All to efforts by decades treatment accordingly, people proprietary team difficult driven CNS our are come. of entirely And internal for exceptional a IP protected dedicated compounds advancing our are by come platform the and exclusivity seriously chemistry, innovation; stemming disorders.
PTSD, of compounds we across processes sensory for targeting. our in to processes animal pharmacology a models plasticity, have processing brain ultimately the attention, NMDA leading NMDA vital in is drug target NMDA and the receptor target disease. are for and are brain, normalize way called the compounds The modulate The to physiology, Each pivotal critical which Our NMDA element to to the interest a in is receptor function and memory. discovered receptors with learning pain, case modulators. these are enhanced our been others. underlying most in discussion associated of targeted regulate cognitive to-date, receptor impairment NMDA and They chronic But underpins including and drugs agonists, compounds and our mostly synaptic preclinical numerous are indications CNS in core receptor, in receptor. bind NMDA function. resulting a developers They normal abnormal of disorders, or antagonists which uniquely and decades. biological, receptor NMDA compounds the many pure of receptors developed differences unlike
mediated preclinical launched NMDA address enhancing modulators molecules. synaptic plasticity. by only We a few stage disruption Aptinyx novel of in this Our receptor XXXX the with middle
marked Now, later, be of in This product a programs team half years have challenging X the CNS on targeting of of X. and and we Phase another candidates proud the could productivity study patent I to successful closing and issued initiating XXXX and our two level this remarkable are four just three on cusp a pipeline. is also efforts was our These of indications. IP Phase not we of more across the results progress course, in our by significant June. point. Aptinyx, year This of initial state clinical to a get year, of past offering built robust back for the important additional public with
clinical of of our candidates are composition product covered now by stage IP. All matter issued
Now, our let's discuss stag of clinical each in some programs detail.
active NYX-XXXX therapy with conditions. Phase start already from had two from first studies offered that in even at electrophysiology safety volunteers, will healthy confirmation excellent which in only in they is XXXX, in We human engage pain Coming had but pain chronic NYX-XXXX the for the NYX-XXXX that results reported established in as pain. mediated processes developing present chronic, and an a we profile, X not into central also very dose long-term high that we readily NMDA and are linear blood-brain concentrations receptor it These level. November But and it NMDA mediated. is predictable a peripherally in receptors pharmacokinetic In mediated the effect pain system. XXXX, ample NMDA particularly of very achieves nervous the receptor and Chronic profile crosses important acute and different barrier with in processes. had downstream
that be of reported the We were results, processing central in it characterized symptoms, half But, a compelling biomarkers. NYX-XXXX fibromyalgia, with a and and pain year. well. analysis and pain central We connectivity perception [ph] Alongside known alleviation we as acute manifested that with moves, the the the biomarker about patients study in we of burnt the complete in and as and activity central the the effect life. when of report of addressed activity plan to well as highly this evaluate we in processing The last study. in by regions improvement through brain. processing receptor is pain in Lyrica techniques statistical available in in and by can subjective this the internal the brain to normalization central NYX-XXXX that as the imaging imaging resulted pain of just perception believe this seen quality same We pain, improvement who are becomes result changes to results mechanism pain of found pain patients Our their this be these active in significance our is that this pain are of function. these December approved interim these of in that this with consistent pain from Lyrica, we these responded associated patients precedent results, only first [indiscernible] the the and cognitive pain. positive imaging in processing. showed for very study are change XX on in XX These demonstrating Based symptoms central the and the we neuroimaging drug this the changes full study. not centrally NMDA increasingly study these of The peripheral fibromyalgia. endpoint a investigator patients, to significant just study, fMRI to other symptoms objective biomarkers analysis comparable In to fibromyalgia of of in on fibromyalgia, exploratory improvement primary statistically patients study processing. NYX-XXXX series in In of images and saw actual know using confirmed reported is
our Let’s now the DPN. NYX-XXXX study discuss patients completed painful in result of with of XXX
that four the pain. did path primary forward While in endpoint, questions the meet study inform critical not did its it answer chronic
asked had with And saw we DPN is and in safe no treatment-related First, to profile events, a adverse tolerability patient an NYX-XXX similar excellent overall serious event NYX-XXXX safety if that adverse we placebo. population. and
we dose the And and the most level greater is identify XX-fold our exhibits studies, dose activity future preclinical from dose that effective projections indeed the there Second, work. XX-milligram appropriate see with across looked if level range our a as than dose aligned to did we others. for a
of use the that endpoints pain quality including evaluating understand life, dose Fourth, common magnitude we response activity relief. function. pain NYX-XXXX. shows we that the XX-milligram patients’ the inform if had sleep, endpoints, Third, parameters across saw if symptom wanted the to we and And as and endpoints activity or of various of comorbidities we the chronic are NYX-XXXX wanted to to across know characteristics likelihood there evaluate to well multiple the as
for and that detailed have a periods that set. significant just have the announced for treatment the been is It of we we conference, statistically As clinically from revealed first analysis last NYX-XXXX Cowen who week time, of patients meaningful. completed very from and benefit the suffering full DPN data at is experienced time longer
how analysis and deduction derisked dose statistically January, in was the following the has average XX points pain study on Numeric data in further results daily, didn't from observed milligrams group. DPN In week the patients in dose to best endpoint analysis informed Scale the further XXX placebo the study This painful top-line our X.XX three in gives pain. separation strategy was of the subsequent set namely in than four greatest the from all the us these milligram study. and the of an Rating we reported at on XX January, readout although readout showed that tested, significant better the levels Of see milligrams questions. has XX, placebo, population, in So, placebo, that a NYX-XXXX we XX-point and total with full study. separation In answered XX- the of from top-line primary in
concomitant the analgesic were represented the substantially from placebo pain that X.XX a to saw in showed placebo secondary endpoint observed we the a quite we increased concomitant as of XXX greater approaching the points, patients who separation from key well endpoints. Further, total taking subjects not half clinically In these on from on medication points difference. that the not study Importantly, average points point as and analgesic patients, meaningful separation patients a X.XX about primary a population. reduction medication
important in future Although be achievable, steps. new very difficult, plan patients initially we be turned not quite all as considered observation to conmed out an to on
four, did the may patients. improved in effect plateau Another [ph] We larger with a week the that required see of manner as final treatment. week reach the a endpoints, duration studies, key Across four a XX treatment XX-week not dose a usually was effect at for the across therefore the finding longer of linear milligram multiple weeks. such the drug study effect
many data. Of rich patient beyond dataset this course, of top-line provides endpoints the with in study a size first the
are of saw population, in the the improvement clinical In the in of placebo. advanced the effect who patients, over the study exhibited NYX-XXXX very last after first acquisition more DPN for the pronounced XXX analysis X.XX-point patients for time and a NYX-XXXX. revealed population group. was more four DPN subgroup points endpoints. scores well relevant of of just sub in effect significant mechanism medication. is placebo. These reduction patients This significance. overall has concomitant increase, further we to DPN XX baseline pain resulted week, diagnosis that [ph] the these to the pain for announced study above As across incremental a of improvement from other patients patients effects increasing DPN threshold advanced taking we dose to is of large NYX-XXXX in And years, an these that week were X.XX DPN, even full were in milligram sizes, as of statistically In diagnosis points data advanced not of scores This the in analgesic represented X.XX XX-milligram or with four
centralized mechanism and I earlier, perceived works pain. patients discussed increasingly when is the these prolonged to As experience processed pain address chronic that that essentially
as a relief group is treatment. rationale usually would why in benefits this there a So, patients to experience that circle of of patients treatment mechanistic experience to response symptom very This greater is from NYX-XXXX. strong not does
are studies from in often reason. they DPN fact, this In painful excluded for
is years was for of handful patients four this patients. allowing this not observe just to a And rigorous study study. a a had the patients NYX-XXXX in analysis benefit these of a half small future of for focus practical of of encouraging. highly subset longer, or this Nearly and DPN in So, diagnosis
we of efficacy the these on not robust DPN patients worst these importantly, pain, consistent, was daily across interference measures observed just walking, on very in improvements endpoint, and sleep showed endpoints one the including NYX-XXXX Finally and others. patients advanced pain
for to as results these sound We Scientific with greater presenting have have scientific the a potential. Milwaukee DPN that I this provide foundation a painful looking and fibromyalgia the we these just therapeutic further on of detail in strong Meeting experts DPN findings, and to by potential differentiated early pressure NYX-XXXX clinical Based plan overwhelmingly in tested studies excited the and and regarded in We're data are analyses highlight April. and findings shared, now investigation These and we at and year. of forward its informed have these about Pain compelling. are they independent number conclusions totality Society of American in later initiate clinical that
needs believe a that in the efficacy are NYX-XXX Now, PTSD to over the has mechanism. suffer therapies many disorder. unmet United to marked X with PTSD It let's post-traumatic that program of address States PTSD. are treat to our by inadequate is the significant potential from available NYX-XXX effects. that turn differentiated side alone and million in in In people stress estimated We the
study. NYX-XXX very models core and enroll In including is PTSD. study patients comparison who study We in NYX-XXX in dysfunction traumatic receive that acceleration will dysfunction plasticity will be and to have consolidation parallel compound extinction. record or or the periodically learning underlying address in that approximately the either study The initiated the in We memory as patients a this XX-milligram is patients. NYX-XXX sequential, we reaction and which By response highlight these extinction seen PTSD, PTSD. preclinical of memory mitigate develop may extinction with this eight-week event, that an synaptic a fear over is associated in course with of at in of placebo patients announced non-traumatic and subsequent learning learning The response fear result to of stimuli. and who that compelling our is of February process a processes, anxiety models natural first enhancing demonstrated the with XXX results is to of design the placebo NYX-XXX in able and
CAPS, are on the the study effects PTSD as NYX-XXX is or both PTSD including the evaluates in symptom as Clinician-Administered symptoms diagnostic tool anticipate various which a We reporting study. a of this multiple and of in standard evaluating XXXX. endpoints, endpoint Scale data and We across first domains half used PTSD from
volunteer evaluating study dose nearing brain safety, tolerability, exposure X now in to completion are we pharmacokinetics Moving NYX-XXX, which the we are of and multiple levels. Phase our the healthy spend of
its the to We study We first our report patients data to later this plan efficacy with this in from study NYX-XXX half of cognitive to year. in expect the and into Parkinson's evaluate impairment. take X first safety Phase year disease
While and recognition people impairment United an disease efficacy symptoms, of that is about for some to the the suffering therapy in these loss patients. of them States is one impairment Parkinson's, million Currently, there's the Parkinson's only by that approved its disease. X form from there cognitive suffer offers it motor from Of characterized estimated cognitive often is the it increasing half neurons of dopamine modest with impairments. cognitive most of in is the Parkinson's in associated
rapid restored was reverse levels. very cognitive saw excited seen the cognitive of we In following they for On are several based preclinical, NYX-XXX We on prospects that translatable neurons. have relevant, on and effects that NYX-XXX compelling able in resulted model These cognitive of disease [ph] including back very depletion impairment performance the model, results dopamine of some Parkinson's highly baseline in a healthy to months. non-human this primate. about measures, deficits was improved we to were
with and encouraging motor us did to not Additionally, findings this the it study, on not in and numerous and CRO in experts work model interfere used we L-DOPA. including compounds any on symptoms, effect field, the it. highly These negative years antiparkinsonian with the NYX-XXX are has of other did we have saw that has evaluated which impact the for
later eager initiate patients. I We that to to mentioned, are this very as NYX-XXX year. plan evaluate we And
clinical our will we objective clinical expand preclinical is to XXXX, in findings on this ahead, acutely from execution, and past the Looking focused on be year. overarching and
candidates pain, We by clinical to year. call end cover and full-year in fourth our and that, Ashish of our chronic each financial expect this and four the studies development cognitive advancing Phase the PTSD, progress product With the have to our I now over will X across of quarter are turn impairment to of results.
